Delivers flexibility, precision, and speed for world’s leading biopharmaceutical and oncology organizations
Boston, MA, January 13, 2020 – ConcertAI, a market leader for Real-World Data (RWD) and enterprise AI technology solutions for precision oncology, announced today the release of eurekaHealth 3.0, the first combination of use-case aligned RWD and AI technologies to deliver high-performance real-world evidence (RWE) insights and services with unprecedented speed, precision, and confidence for oncology clinical development in the life sciences industry.
With eurekaHealth 3.0, ConcertAI combines the largest and most comprehensive array of research-ready RWD with advanced AI capabilities for “on-demand” precision analyses and patient insights. Researchers across the enterprise can now readily access data, including clinical and genomic data, engineered for and aligned to specific use-cases– through intuitive drag and drop and natural language search – to ask meaningful questions and gather insights quickly.
eurekaHealth is a cloud-deployed SaaS platform with a flexible microservices-based architecture that optimizes performance for rapid operations, provides the ability to compare cohorts across different data sets, and integrates into existing workflows—including first and third-party data.
This industry first—the integration of data from multiple electronic medical record (EMR) systems and hundreds of clinical sites with peer-reviewed AI models and technologies – establishes eurekaHealth 3.0 as the emerging standard for RWE. Now, rapid, precise, and flexible RWE is available to a broader group of researchers. Production-ready data and technology solutions standardize key analyses and reduce times for study feasibility and design by 50 percent.
ConcertAI is deploying this new version of eurekaHealth in multi-disease collaborations with some of the world’s largest biopharmaceutical companies to optimize drug development and advance patient therapies and outcomes:
- ConcertAI Establishes Real-World Data and AI Collaboration with Janssen
- Pfizer Expands Collaboration with ConcertAI to Accelerate Real-World Evidence and AI Technology Capabilities for Regulatory Purposes in Additional Disease Areas
- Bristol-Myers Squibb and ConcertAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovation
ConcertAI’s eurekaHealth 3.0 deploys AI models that derive key endpoints and variables from structured and unstructured data for greater utility. ConcertAI models for augmenting RWD and predicting characteristics of a patient population were validated in peer-reviewed publications and presented at ISPOR 2019 and ASCO 2019. eurekaHealth provides ready access to the uniquely engineered ConcertAI data products, including RWD360™ for highly representative structured data, Patient360™ for deeply curated, off-the-shelf research-grade data in five tumor types, and Genome360TM, the combination of clinical insights and the broadest next-generation sequencing mutation coverage.
“This is the first precision oncology system that integrates advanced, scalable, production-ready data science and ConcertAI’s superior RWD for high-performance RWE – to become an integral part of the enterprise operating model,” said Jeff Elton, PhD, CEO of ConcertAI. “Researchers no longer have to make compromises when it comes to precision and productivity.”